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Abstract
Aims Although cardiac resynchronisation therapy (CRT) is an
established treatment to improve cardiac function, a signifi-
cant amount of patients do not experience noticeable improve-
ment in their cardiac function. Optimal timing of the delay
between atrial and ventricular pacing pulses (AV delay) is of
major importance for effective CRT treatment and this opti-
mum may differ between resting and exercise conditions. In
this study the feasibility of haemodynamic measurements by
the non-invasive finger plethysmographic method (Nexfin)
was used to optimise the AV delay during exercise.
Methods and results Thirty-one patients implanted with a
CRT device in the last 4 years participated in the study. During
rest and in exercise, stroke volume (SV) was measured using
the Nexfin device for several AV delays. The optimal AV
delay at rest and in exercise was determined using the least
squares estimates (LSE) method. Optimisation created a clin-
ically significant improvement in SV of 10 %. The relation
between HR and the optimal AV delay was patient dependent.
Conclusion A potential increase in SV of 10 % can be
achieved using Nexfin for optimisation of AV delay during
exercise. A considerable number of patients showed benefit
with lengthening of the AV delay during exercise.
Keywords Cardiac resynchronization therapy .
Atrio-ventricular delay . Optimisation
Introduction
In a subgroup of heart failure patients, treatment by cardiac
resynchronisation therapy (CRT) can be beneficial [1, 2] and
is mostly combined with ICD therapy [3]. Although several
studies have confirmed the effect of CRTon improvement in
cardiac function, still one-third of patients do not experience
noticeable gain from CRT [1, 2, 4, 5].
To increase the rate of responders, proper timing of pacing
pulses may play a role. The proper timing of pacing pulses is
of major importance for the created stroke volume and the
treatment effect of CRT [6, 7]. As CRT improves left ventric-
ular function and increases exercise capacity, optimisation of
CRT during exercise seems more meaningful than at rest.
Since earlier studies show diverse outcomes regarding the
optimal timing interval during higher heart rates, with per-
individual variation, optimisation of the AV delay should
include both measurements at rest and during exercise [8–12].
The gold standard method for general measurement of
haemodynamic improvement is invasive [13]. This tech-
nique is too elaborate for routine CRT optimisation and
certainly not suitable during exercise. For that reason, non-
invasive methods to assess the haemodynamic state have
been developed. Echocardiography is widely used but is
challenging during exercise.
Recently Van Geldorp et al. [14] studied the feasibility of a
non-invasive method provided by a Nexfin device (Edward
Lifesciences BMEYE B.V., Amsterdam, the Netherlands) to
continuously monitor beat-to-beat haemodynamics, using a
finger cuff. Van Geldorp et al. concluded that this is a prom-
ising tool in the individual optimisation of CRT. The Nexfin
showed a good performance on the measurement of beat-to-
beat stroke volume (SV) changes, the assessment of relative
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effects induced by CRT and on the determination of the
optimal AV delay. The precision of Nexfin in assessing beat-
to-beat SV changes was determined at around 6 %, which is
considered precise [14–17]. In this study the Nexfin device
was used to determine the optimal AV delay during different
heart rates during exercise.
In our study the feasibility of a non-invasive finger ple-
thysmographic method (Nexfin, BMEYE B.V., Amsterdam,
the Netherlands) in optimisation of atrioventricular delay
(AV-delay) during exercise was assessed.
Materials and methods
The Nexfin uses the volume-clamp method introduced by
Czech physiologist Professor J. Peñaz [18]. Herein the cuff
pressure provides an indirect measure of intra-arterial pres-
sure. To correct the distortion in finger pressure relative to
brachial artery pressure, a frequency-dependent filter is used
to restore the waveform at the brachial level. The stroke
volume is computed by using CO Trek, a model-based meth-
od and algorithm which uses a nonlinear, self-adaptive three-
element Windkessel model of the aortic input impedance.
All patients known in the Cardiology Department of the
Medisch Spectrum Twente implanted with a CRT device in
the last 4 years were included according to the inclusion
criteria, as shown in Table 1. Using these criteria a patient




First, the rate-responsive AV delay of the CRT device is turned
off, patients are seated on the exercise bicycle, connected to a
12-lead surface ECG registration system (Philips StressVue,
Philips, the Netherlands) and to the Nexfin system using the
proper size finger cuff and heart reference system. After
application of the measurement devices, some minutes of rest
are included to create steady-state conditions in the patient as
well as in the measurement devices. The VV delays were not
reprogrammed in order to change only one parameter (AV
delay) which could influence the haemodynamic circum-
stances. Most of the patients had a VV delay of −20 or -30 ms.
Rest protocol
The optimal AV delay at rest is tested by programming AV
delays starting from 40 ms with increments of 20-ms steps,
until either intrinsic conductance starts or until a maximum
AV delay of 340 ms is reached. When the device can not be
programmed in 20-ms steps (St JudeMedical Systems devices
when programming AV delays >200 ms), the test is continued
using 25-ms steps. When the VV delay precludes the pro-
gramming of an AV delay of 40ms, the first tested AV delay is
set to 60 ms or even 80 ms. Prior to each programming step,
baseline haemodynamic parameters were collected (10 s av-
erages). Next, the AV delay was reprogrammed and
haemodynamic changes compared with baseline were mea-
sured, preventing influences of slow haemodynamic changes.
Minimally two beats after reprogramming a ten-second aver-
aging of haemodynamic parameters is performed. After this
averaging, the AV delay is programmed back to the baseline
setting. After a minimum of 25 s, the preparation for the
following AV delay setting starts again. After completion of
this rest protocol, the optimal rest AV delay is determined as
the highest SV increase from baseline to tested AV delay. This
is the ‘working’ optimal AV delay which is used in the
exercise protocol that follows. The complete protocol of the
study can be found in Appendix A.
Exercise protocol
The exercise protocol consists of three stages. During the first
stage, the target heart rate is set at 15 beats per minute (bpm)
Table 1 Inclusion criteria
CRT = cardiac resynchronisation
therapy, ESC = European Society
of Cardiology, LBBB = left bun-
dle branch block
- Intact AV conduction.
- Patients age <80 years
- CRT implanted on indication of LBBB and according to ESC guidelines
- Able to complete a supine bicycle exercise stress protocol
- Sinus rhythm, no patients with e.g. permanent atrial fibrillation can be included
- No prior valvular surgery.
(might alter the physiology of the heart cycle)
- CRT in situ for minimally 6 months.
(after 6 months the major part of remodelling is assumed to be completed)
- No history of irreversible ischaemia in the heart; no previous myocardial infarction or ischaemia present
(irreversible ischaemia might have a major influence on heart cycle physiology and the response to CRT)
- Posterolateral placement of the left ventricular electrode
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above the resting heart rate. In stage two and three, the target
heart rate is 30 and 45 bpm higher, respectively, if tolerated by
the patient. The patient is instructed to start pedalling at a
comfortable cadence of 60 rotations per minute. This cadence
is indicated on a screen on the handlebar of the bike. To reach
the target heart rate the bicycle’s resistance is adjusted. When
the target HR is reached, this HR is maintained within 5 bpm
from this target rate by adjusting the bicycle’s resistance and
coaching the patient in the pedalling speed. The AV delays
tested during the exercise protocol range from 80 ms shorter
than the working optimal AV delay to 80 ms longer. After
finishing the first stage, the second and subsequent third stage
are performed using the same protocol. The test is ended when
stage three has been completed or when the patient becomes
too fatigued to continue cycling. (See also the flowchart of the
test protocol in Appendix A.)
Analysis
Optimal AV delay
Baseline SV, averaged over the 10 s measured before AV
delay programming, is subtracted from the averaged SV
measured during tested AV delay. As such, the change in
SV (ΔSV) created by the tested AV delay is found.
ΔSV mLð Þ ¼ SV tested AV delay mLð Þ−SVpreceding baseline mLð Þ
Whinnett et al. [19] demonstrated that the curve of SV
response at increasing AV delays fits closely to a second-
order polynomial with a maximum. To determine the optimal
AV delay we used the least square estimates (LSE) method
(Matlab, The Mathworks, USA). This is based on
minimisation of the sum of the squared residuals, with a
residual being the difference between a measured value and
the fitted value provided by the 2nd order polynomial curve.
The point in which the fit over theΔSV points reaches its
maximum is selected as the optimal AV delay for that stage.
It is expected that the LSE creates a parabola with a top.
When, however, a parabola with a minimum is created or
when the calculated maximum is not within reasonably
programmable AV delays (<20 or>intrinsic guidance) the
stage is excluded from further analysis. Per patient the rate
dependency of the optimal AV delay in the eligible stages is
assessed. The mean change in optimal AV delay in millisec-
onds per increase in HR in beats per minute is calculated.
Beneficial effect of optimisation
The beneficial effect of optimisation is calculated as the per-
centage of increase in SV potentially to be created by optimi-
sation per stage. Therefore the mean ΔSV corresponding to
the minimum of the polynomial fit per stage is subtracted from
that corresponding to the maximum. This potential increase is
divided by the measured mean SVat the minimum of the fit.
The minimum of the polynomial fit is determined consid-
ering reasonably programmable AV delays, the minimum
being 40 ms and maximum being 20 ms below AV delay
creating intrinsic guidance since in CRT continuous pacing
should be preserved.
Results
Between January 2006 and December 2011, 406 patients
received a CRT device. Fifty-three patients met the inclusion
criteria. Twenty-two of these patients were not included in
the study because of the following reasons: insufficient pe-
ripheral circulation to perform the test (n=1), and not willing
to perform a cycling test (n=21).
The 25 male and 6 female patients all had a CRT-D device
(13 Medtronic, 14 St. Jude, 4 Boston Scientific / Guidant).
All patients were receiving adequate ventricular pacing with
an average ventricular pacing fraction of 98 %. The mean
time after implant was well above 6 months. Therefore it was
assumed that cardiac remodelling had ended. See Table 2 for
further patient characteristics.
Optimal AV delay
A total of 90 optimisation stages were performed. For all tested
AV delays in these 90 stages the ΔSV was calculated. An
example of this for one stage in one patient is shown in Fig. 1.
A maximum AV delay could be determined for all tested
stages in five patients. In 19 patients there were two or more
stages in which a maximum AV delay could be determined.
Table 2 Patient characteristics
Sex Male 25 patients
Female 6 patients
Age 65.8±8.9 year
CRT device CRT-P 0 patients
CRT-D 31 patients
Device brand Medtronic 13 patients
St Jude Medical 14 patients
Boston/Guidant 4 patients
EF before implant 26±7 %
Time after implant 32.9±14.5 months
Ventricular pacing 98±2 %
Max stage reached Stage 1 10 patients
Stage 2 14 patients
Stage 3 7 patients
CRT = cardiac resynchronisation therapy, EF = ejection fraction
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Using the LSE method in 55 (61 %) of the stages a maximum
AV delay could be determined. See Table 3 for specifications
per stage. The mean optimal AV delay was 118±32 ms during
rest stages, 121±40 ms during stage 1, 129±30 ms during
stage 2 and 109±31 ms during stage 3. The averaged optimal
AV delay over all 54 stages was 121±34 ms. See also Table 3.
When considering the optimal AV delay during exercise
(in patients with two or more eligible stages), a shortening
(1.9±0.9 ms/bpm) of optimal AV delay was found in eight
patients (42 %). In four patients (21 %) a lengthening (2.5±-
1.7 ms/bpm) of optimal AV delay was found. In four patients
(21 %) the AV delay did not change with increasing heart
frequency, i.e. the optimum stayed within 10 ms. In the
remaining three (16 %) patients the optimal AV delay fluc-
tuated with increasing heart frequencies but did not solely
shorten or lengthen.
Beneficial effect of optimisation
In this study a mean optimisation effect of 10 % was found. In
12 stages a potential increase in stroke volume between 0 and
5 % was observed, in 21 stages an effect between 5 and 10 %.
In the resting stages an effect of above 10 % was observed.
See also Fig. 2.
Discussion
This study was designed to assess the feasibility of Nexfin in
optimisation of AV delay during exercise based on SV dif-
ferences. The Nexfin device was used to determine the effect
of HR increase during different levels of exercise on the
optimal AV delay. Optimisation of the AV delay resulted in
a 10 % potential SV increase. This is a clinically relevant
increase indicating that the individual patient could benefit
from optimisation by Nexfin during exercise.
The optimal AV delay per stage was determined using
Nexfin. Assuming the relation between ΔSVand increasing
AV delay can be described by a second order polynomial
function, an optimal AV delay could be determined in 61 %
of the stages. The other stages showed a fit with a minimum
or a fit with a maximum, which was not within reasonably
programmable AV delays (<20 or>intrinsic guidance).
The mean optimal AV delay found at rest was 118 ms. This
indicates that for some patients, the typical default settings
(120 ms) can be considered optimal. However, a large stan-
dard deviation in optimal AV delay was found. Since it cannot
be predicted for whom the out of the box settings will be
optimal, this is a strong indication that the AV delay should be
optimised individually in every patient with CRT.
In 42 % of the patients eligible for analysis, a shortening in
optimal AV delay was found for increasing heart rates, whereas
21 % showed a lengthening in optimal AV delay. These results
are in accordance with the highly diverse outcomes in earlier
studies [8–12]. The use of different methods for measurement of
SV has been suggested as a possible explanation for this diver-
sity. Another explanation, which our study supports, could be the
patient dependency in rate responsive optimal AV delay.
In currently available CRT devices the AV delay can only
be programmed to a fixed rate or to dynamic shortening,
while lengthening of the AV delay during CRT is not an
option. This study, and the earlier mentioned study by Scharf
[9], indicated a potential benefit of lengthening of the AV













Fig. 1 Optimal AV delay calculation for one stage in one patient. The
points mark theΔSV calculations for the different AV delays. The solid
curve is the individual optimisation curve created by the LSE method.
The optimal AV delay is selected as the maximum of the optimisation
curve (dotted line)
Table 3 Percentage of eligible stages and mean optimal atrioventricu-
lar (AV) delay per stage
Optimal AV delay % with max Mean ± SD
Rest 61 % 118±31 ms
Stage 1 65 % 121±40 ms
Stage 2 57 % 129±29 ms
Stage 3 57 % 109±31 ms
Overall 60 % 120±34 ms
Fig. 2 Increase in SV created by optimisation
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delay for a certain patient group. Because of earlier men-
tioned conflicting evidence on rate adaptive AV delay in the
literature, it is currently advised that the rate responsive AV
delay should be inactivated by default [12, 20]. However
programming rate responsive AV delay ON was encouraged
in the MIRACLE trials [5]. A recent pilot study by
Shanmugam [21] showed that programming rate adaptive
AV delay ON improves exercise capacity and advised to
revise the debate regarding rate adaptive AV delay.
Only a few other devices provide continuous and non-
invasive stroke volume during exercise. The Finometer
(Finapress Medical Systems, Amsterdam, the Netherlands) also
uses the volume clamping and a pulse contour analysis method
to determine stroke volume. However, this device needs frequent
calibration with an upper arm cuff. The Nicom system (Cheetah
Medical, Vancouver, USA) uses bioreactance to measure stroke
volume. These measurements have been found feasible and
reliable for AV delay optimisation. However, this has not yet
been tested during exercise where this may be a challenge due to
the system’s vulnerability to motion artifacts [22].
Limitations
The first limitation is that only 6 female patients were in-
cluded in the study. However, women appear to be generally
underrepresented in patients who receive ICDs and CRT
devices [23]. Secondly, the VV delay was deliberately not
reprogrammed to assess the effect of changing the AV delay
only. Adapting the VV delay as well could have resulted in
an even higher increase of SV. And a third limitation is that
the study only describes the acute haemodynamic effects;
long-term follow-up data will become available next year.
Conclusion
This study is a first step in clinical application of the Nexfin
in AV delay optimisation during exercise. In every patient
AV delay at rest and during exercise should be optimised
individually. A potential increase in SV of 10 % can be
achieved using Nexfin for optimisation of AV delay during
exercise while a considerable number of patients showed
benefit with lengthening of the AV delay during exercise.
Disclosure Wilbert Wesselink is an employee of Edwards Lifesciences
BMEYE, Amsterdam, the Netherlands.
Funding None.
Conflict of interests None declared.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
Appendix A
462 Neth Heart J (2013) 21:458–463
References
1. BristowMR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization
therapy with or without an implantable defibrillator in advanced
chronic heart failure. N Engl J Med. 2004;350:2140–50.
doi:10.1056/NEJMoa032423.
2. Cleland JGF, Daubert J-C, Erdmann E, et al. Longer-term effects of
cardiac resynchronization therapy on mortality in heart failure [the
CArdiac REsynchronization-Heart Failure (CARE-HF) trial exten-
sion phase]. Eur Heart J. 2006;27:1928–32. doi:10.1093/eurheartj/
ehl099.
3. Smith T, Van Dessel PF, Theuns DAMJ, et al. Health care utilisation
after defibrillator implantation for primary prevention according to
the guidelines in 2 Dutch academic medical centres. Neth Heart J.
2011;19:405–11. doi:10.1007/s12471-011-0176-3.
4. Linde C, Leclercq C, Rex S, et al. Long-term benefits of
biventricular pacing in congestive heart failure: results from the
MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am
Coll Cardiol. 2002;40:111–8.
5. AbrahamWT, FisherWG, Smith AL, et al. Cardiac resynchronization
in chronic heart failure. N Engl J Med. 2002;346:1845–53.
doi:10.1056/NEJMoa013168.
6. Auricchio A, Stellbrink C, Block M, et al. Effect of pacing chamber
and atrioventricular delay on acute systolic function of paced pa-
tients with congestive heart failure. The pacing therapies for con-
gestive heart failure study group. The guidant congestive heart
failure research group. Circulation. 1999;99:2993–3001.
7. Auricchio A, Ding J, Spinelli JC, et al. Cardiac resynchronization
therapy restores optimal atrioventricular mechanical timing in heart
failure patients with ventricular conduction delay. J Am Coll
Cardiol. 2002;39:1163–9.
8. Sun JP, Lee AP-W, Grimm RA, et al. Optimisation of atrioventric-
ular delay during exercise improves cardiac output in patients
stabilised with cardiac resynchronisation therapy. Heart. 2011.
doi:10.1136/heartjnl-2011-300278.
9. Scharf C, Li P, Muntwyler J, et al. Rate-dependent AV delay optimi-
zation in cardiac resynchronization therapy. PacingClin Electrophysiol.
2005;28:279–84. doi:10.1111/j.1540-8159.2005.40054.x.
10. StåhlbergM, DamgaardM, Norsk P, et al. Cardiac output response to
changes of the atrioventricular delay in different body positions and
during exercise in patients receiving cardiac resynchronization ther-
apy. Europace. 2009;11:1160–7. doi:10.1093/europace/eup173.
11. Prochnau D, Forberg T, Kühnert H, et al. Optimization of the atrio-
ventricular delay during cardiac resynchronization therapy using a
device for non-invasive measurement of cardiac index at rest and
during exercise. Europace. 2011. doi:10.1093/europace/eur296.
12. Melzer C, Bondke H, Körber T, et al. Should we use the rate-
adaptive AV delay in cardiac resynchronization therapy-pacing?
Europace. 2008;10:53–8. doi:10.1093/europace/eum257.
13. Pugsley J, Lerner AB. Cardiac output monitoring: is there a
gold standard and how do the newer technologies compare?
Semin Cardiothorac Vasc Anesth. 2010;14:274–82. doi:10.1177/
1089253210386386.
14. Van Geldorp IE, Delhaas T, Hermans B, et al. Comparison of a non-
invasive arterial pulse contour technique and echo Doppler aorta
velocity-time integral on stroke volume changes in optimization of
cardiac resynchronization therapy. Europace. 2011;13:87–95.
doi:10.1093/europace/euq348.
15. De Wilde RBP, Geerts BF, Cui J, et al. Performance of three
minimally invasive cardiac output monitoring systems. Anaesthe-
sia. 2009;64:762–9. doi:10.1111/j.1365-2044.2009.05934.x.
16. De Wilde RBP, Schreuder JJ, Van den Berg PCM, et al. An eval-
uation of cardiac output by five arterial pulse contour techniques
during cardiac surgery. Anaesthesia. 2007;62:760–8. doi:10.1111/
j.1365-2044.2007.05135.x.
17. Van Lieshout JJ, Toska K, Van Lieshout EJ, et al. Beat-to-beat
noninvasive stroke volume from arterial pressure and Doppler
ultrasound. Eur J Appl Physiol. 2003;90:131–7. doi:10.1007/
s00421-003-0901-8.
18. Peñaz J. Photoelectric measurement of blood pressure, volume and
flow in the finger. Dresden. 1973 p. 104.
19. Whinnett ZI, Davies JER, Willson K, et al. Haemodynamic effects
of changes in atrioventricular and interventricular delay in cardiac
resynchronisation therapy show a consistent pattern: analysis of
shape, magnitude and relative importance of atrioventricular and
interventricular delay. Heart. 2006;92:1628–34. doi:10.1136/
hrt.2005.080721.
20. Mokrani B, Lafitte S, Deplagne A, et al. Echocardiographic study
of the optimal atrioventricular delay at rest and during exercise in
recipients of cardiac resynchronization therapy systems. Hear
Rhythm. 2009;6:972–7. doi:10.1016/j.hrthm.2009.03.023.
21. ShanmugamN, Prada-Delgado O, Campos AG, et al. Rate-adaptive
AV delay and exercise performance following cardiac
resynchronization therapy. Hear Rhythm. 2012;9:1815–21.
doi:10.1016/j.hrthm.2012.07.001.
22. Khan FZ, Virdee MS, Pugh PJ, et al. Non-invasive cardiac output
measurements based on bioreactance for optimization of atrio- and
interventricular delays. Europace. 2009;11:1666–74. doi:10.1093/
europace/eup358.
23. Ghani A, Maas AHEM, Delnoy PPHM, et al. Sex-based differences
in cardiac arrhythmias, ICD utilisation and cardiac resynchronisation
therapy. Neth Heart J. 2011;19:35–40. doi:10.1007/s12471-010-
0050-8.
Neth Heart J (2013) 21:458–463 463
